Shilanski & Associates Inc. Sells 2,737 Shares of Axon Enterprise, Inc $AXON

Shilanski & Associates Inc. reduced its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 39.9% in the 3rd quarter, Holdings Channel reports. The firm owned 4,121 shares of the biotechnology company’s stock after selling 2,737 shares during the period. Shilanski & Associates Inc.’s holdings in Axon Enterprise were worth $2,957,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter worth $480,000. Axiom Investors LLC DE bought a new position in Axon Enterprise in the 1st quarter worth $93,088,000. Baird Financial Group Inc. lifted its position in Axon Enterprise by 5.9% during the 1st quarter. Baird Financial Group Inc. now owns 5,987 shares of the biotechnology company’s stock worth $3,149,000 after acquiring an additional 333 shares during the last quarter. Atreides Management LP bought a new stake in Axon Enterprise during the first quarter valued at about $33,083,000. Finally, Federation des caisses Desjardins du Quebec grew its position in shares of Axon Enterprise by 10.8% in the first quarter. Federation des caisses Desjardins du Quebec now owns 7,627 shares of the biotechnology company’s stock valued at $4,011,000 after purchasing an additional 746 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

AXON opened at $572.11 on Wednesday. The stock’s 50 day simple moving average is $594.96 and its 200-day simple moving average is $697.64. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57. The stock has a market cap of $45.15 billion, a PE ratio of 181.05, a P/E/G ratio of 133.34 and a beta of 1.40. Axon Enterprise, Inc has a 1 year low of $469.24 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The business had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm’s quarterly revenue was up 30.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.45 EPS. Sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. JMP Securities reissued a “market outperform” rating and set a $825.00 price objective on shares of Axon Enterprise in a research report on Monday, September 29th. The Goldman Sachs Group cut their price target on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Barclays reduced their price objective on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Zacks Research lowered shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Finally, Wall Street Zen cut shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $802.71.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the completion of the transaction, the president owned 249,502 shares in the company, valued at $137,874,805.20. This trade represents a 7.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Brittany Bagley sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the sale, the chief financial officer owned 103,501 shares in the company, valued at approximately $60,030,580. This represents a 1.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 60,540 shares of company stock worth $35,632,038 in the last 90 days. 5.70% of the stock is currently owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.